Polfa Tarchomin S.A
Developing Generics with Purpose: Where Pharmaceutics, Regulation and Patient needs Intersect
Rafal Lunio
In recent decades, the generic pharmaceutical industry has undergone a significant transformation. No longer is the development of generics merely an exercise in replicating the reference listed drug (RLD); instead, it increasingly requires a sophisticated interplay between pharmaceutical formulation science, regulatory compliance and patient-centric considerations. As the generic sector continues to mature, the ability to balance regulatory requirements with pharmaceutical innovation and patient-centered design — while also incorporating necessary innovations, for example those supported by systemic funding programs — will become a defining competitive advantage.
The Traditional Model: Limitations of Simple Replication
Historically, the development of generic drugs focused on achieving chemical and bioequivalent sameness with the originator product. The primary regulatory goal was to match the active pharmaceutical ingredient (API) and ensure therapeutic equivalence, typically validated through pharmacokinetic bioequivalence studies (FDA, 2021; EMA, 2010). This approach, while scientifically sound, often neglected nuanced aspects of patient experience such as ease of administration, tolerability and adherence.
This traditional paradigm presumed that pharmaceutical equivalence (Q1/Q2 sameness) would inherently guarantee patient equivalence. Q1 sameness refers to identical qualitative composition (same excipients), while Q2 sameness requires identical quantitative excipient content. In some cases, Q3 sameness (similarity in microstructure and physical properties) is also mandated, particularly for non-oral dosage forms (FDA, 2021).
However, emerging clinical data have demonstrated that even minor variations in excipient composition, dissolution profiles, or drug release characteristics can meaningfully impact patient adherence, therapeutic outcomes and even adverse event profiles, especially in vulnerable populations such as pediatrics, geriatrics, or individuals with polypharmacy (Mahmood, 2020; Al Ameri et al., 2012).
The Rise of Patient-centered Pharmaceutics
Modern generic drug development increasingly incorporates patient-centric pharmaceutical design (PCPD), which emphasises the formulation of products that not only meet regulatory standards but also enhance patient usability and adherence (Domingues et al., 2023). Factors such as tablet size, swallowability, taste masking, dosing flexibility and administration convenience are now recognised as critical formulation parameters, particularly for chronic therapies requiring long-term compliance.
Modern generic drug development increasingly incorporates patient-centric pharmaceutical design (PCPD), which emphasises the formulation of products that not only meet regulatory standards but also enhance patient usability and adherence
For example, a recent European Medicines Agency (EMA) reflection paper emphasised that formulation choices for pediatric medicines must consider palatability, age-appropriate dosage forms and excipient safety profiles (EMA, 2006). Similarly, the International Council for Harmonisation (ICH) guidelines increasingly emphasise the need for lifecycle management of formulations to optimise patient outcomes (ICH Q12, 2020).
Regulatory Considerations: More than Bioequivalence
While bioequivalence remains a cornerstone of generic drug approval, regulatory agencies worldwide are progressively refining their expectations. The US FDA's Office of Generic Drugs (OGD) and EMA have both recognised that achieving Q1/Q2 sameness may not always be feasible or sufficient, especially when reference products contain complex or proprietary excipient systems.
Furthermore, regulators are increasingly attentive to excipient functionality and its impact on drug release characteristics. Modifications in manufacturing processes, polymorphic forms, or excipient grades can all influence dissolution, absorption and stability, even when API identity is maintained (Zhang et al., 2004).
In addition, regional regulatory variability poses additional challenges. For example, certain excipients may be acceptable in Europe but restricted in Asia or the Middle East due to differing local pharmacopoeial standards or cultural considerations (Hasan et al., 2021). Therefore, global generic development demands not only technical expertise but also regulatory intelligence to navigate multi-jurisdictional compliance.
Case Example: Modified Release Formulations
Consider the development of modified-release (MR) generics, where achieving therapeutic equivalence is particularly challenging. Even minor deviations in matrix composition or coating thickness can alter release kinetics, potentially compromising bioequivalence or safety (García-Arieta & Gordon, 2012). Regulatory agencies often require robust in vitro-in vivo correlation (IVIVC) models and comparative dissolution studies to justify formulation differences and demonstrate therapeutic equivalence.
Moreover, MR formulations often require patient-centric considerations such as reduced pill burden, avoidance of peak-trough fluctuations and maintenance of once-daily dosing regimens, which further complicate formulation design.
The Future: Integrated Formulation Strategies
As the generic sector continues to mature, the ability to balance regulatory requirements with pharmaceutical innovation and patient-centered design will become a defining competitive advantage. Formulation scientists and regulatory affairs professionals must collaborate closely from early development stages to anticipate regulatory expectations while proactively addressing patient needs.
Digital formulation tools, advanced modeling and real-world evidence (RWE) are likely to play a growing role in bridging the gap between laboratory development and clinical performance. In parallel, regulatory frameworks may continue evolving to provide more structured pathways for adaptive formulation development that addresses both equivalence and patient-centered outcomes (Eskola et al., 2021).
Towards patient-optimised generics
The development of generic drugs has evolved far beyond simple replication. Today’s successful generic products result from an intricate synthesis of pharmaceutical science, regulatory foresight and genuine attention to the patient experience. By embracing this multidimensional approach, the generics industry can continue to deliver high-quality, accessible and patient-optimised therapies that fulfill both regulatory and clinical expectations.
